Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Ibrutinib Treatment of Relapsed CLL Following Allogeneic Transplantation: Sustained Disease Response and Promising Donor Immune Modulation Ryan, C. E., Logan, A. C., Rezvani, A., Kamdar, M., Nakasone, H., Sahaf, B., Otani, J., Kong, K. A., Klinger, M., Faham, M., Coutre, S., Miklos, D. B. ELSEVIER SCIENCE INC. 2015: S307–S308
View details for DOI 10.1016/j.bbmt.2014.11.490
View details for Web of Science ID 000348633000446